We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The sooner a quality CEO is appointed the better.
Don't know, but it looks like a creditor of DS finally ran out of patience and took the draconian step of a bankruptcy motion, which costs and attracts all other creditor interests too. It's not just suing DS for a private debt. Maybe DS has now been made bankrupt, the court unwilling to grant him extra time, despite his confidence? Financially very serious for a person, and likely to limit what one can do in business going forward.
Embarrassing for SLN, and some questionmarks over the bod's judgment re DS perhaps (it's not great to have an insolvent CEO) which might spook investors, but hopefully this is only a temporary blip for the company and the SP. The underlying company fundamentals remain, and we're told this issue is an unrelated skeleton rattling in an unrelated cupboard.
SP continuing south today though.
Anybody out there have any idea what on earth is going on here.RNS this morning saying that a non exex. director had been installed as Chairman and that Solomon was looking forward to working with him.Further RNS's to the effect that Solomon had resigned because he was being sued by an individual investor in an Danish firm that had gone bankrupt.Solomon was a Senior Manager at that company between 2016/18.Sounds to me like a pretty lame excuse and something stinks.So an aggrieved investor says he is going to sue you,okay I'll resign before there is any court case which could take years to resolve.Any of you long term investors have any inside track on what on earth is going on here.I saw Solomon doing an interview a couple of weeks and he sounded like the cat who had the cream.
Ditto Spks... this is literally filling up the crater SXX has left in my portfolio !
You have been pretty persistent !
We need @RampDaddy to get us up to 800 p/s ...
If you look down the thread I am the only person to have banged the drum about this share. I am really chuffed to see this moving upwards. Fingers crossed the trend can continue. Plus look out for POG which I am again really excited about. Good luck all and DYOR.
It's interesting that this video had no discussion on
* Extra hepatic
* LP(a)
* Us listing
Extra hepatic was mentioned previously as a collaboration deal. US listing is a no brainer to ask about. Lp(a) is the "crown jewel". The interviewer is not that bad that he doesn't know this, he has asked it all before. Probably has been told not to ask... Hmmm. I think extra hepatic collaboration deal and US listing likely coming in Q1. LP(a) who knows...
Quark results coming soon, as well as first dosing for this sln124.
Gla
Another proactive video
https://www.proactiveinvestors.co.uk/companies/news/908102/silence-therapeutics-ceo-talks-recent-rnai-deals-and-updates-on-critical-sln124-trial-908102.html
As before, in talks with big pharma re deals. At the end he kind of hints a deal could be within 3 months. I think Q1 for sure. Worth a watch.
Yes but not a huge holder I did top up at .42 then took some profit at 402 now my remaining holding is 'free' so will see how far it goes...
I had a 5 pound "guess" out there for the New Year. I think that now has to be 6 pounds by New Year.
Looks like the US RNAi companies will all be up today based of Novartis purchasing the Medicines Company. My guess is that is what is causing the surge today.
https://www.nytimes.com/2019/11/24/business/novartis-medicines-company-cholesterol.html
All the catalysts mentioned previously for this year for SLN are still to come. The threat of a takeover at anytime remains. I had previously guessed at a US listing in Q2. With the "excitement" in the space - US RNAi companies are up 3X+ this year, 50%+ in the past month, and likely another 5%+ today. I think the management will likely capitalize on the "excitement" and so I would bring forward my guess of a US listing from Q2 to likely coming at the end of Q1 - if not earlier.
I would guess this might even touch as high as GBP10 in Q1 based of the current excitement, yet to be announced catalysts, US comparables and the completion or at least announcement of a US listing - and as always a possibility of a takeover.
Conjecture and share prices guesses aside, with a takeover in the space announced, at a minimum this is a buy and hold for a takeover within 2yrs.
atb and gla
Spks
Are you a holder here?
cheers
gosh 5 pounds already !!!
ARWR is now 48.17 up over 6% today, more than 20% in the last 5 business days. Market cap 4.6b just like that... Wow. This thing is now up call it 24X in 2 years.
ARWR closed at 45.28 yesterday up 5.4% for the day. DRNA closed at 19.46 up 8.5% for the day....
The comparable US companies mentioned in Solomons latest proactive video, ARWR Arrowhead and DRNA Dicerna - keep making new highs. ARWR is at 43.85 with a market cap north of 4b now. DRNA is at 18.40 and 1.25b.
The 3 month return of SLN has been just under 100%. Arrowhead has done 50% and Dicerna 30%. The market comparables also just keep going higher - SLN over the next say 2 years still has plenty to go to catch up.
I expect that it is highly likely that another deal of some description will be announced this year. As previous, Solomon could have 4 news item RNS's to release this year, but likely 3 and an absolute minimum of 2. Any positive news event will likely see this higher as the market prices SLN as being a 2 horse race instead of 1 (with MNK).
Not surprising to see the share price consolidate recently. As SLN has been doing that over say the last 2 weeks ARWR and DRNA are both up about 10%.
As before - possible/probable news catalysts to come for this year
* Results of the quark research, which is well delayed.
* Phase1b trials starting for sln124.
* Possible another milestone payment from MNK
* Possible partner deal on another asset but possibly this Extra-hepatic thing
My guess is that this is at 5 or higher by the New Year. In my opinion Solomon has plenty of strings to pull before announcing a US listing in the New Year. That recent video was like watching a cheshire cat present a stock.
gla and atb
Im assuming people have heard of nfx, if you missed the rise this year then i think you have a chance to make it up on there, similar situtaion waiting for similar news that we saw here earlier in year, should rise in similar way
Decided to take a bit of profit and sold some of my shares at 4.02 when I looked back at my account I bought on the 12th June @ 0.45 so probably the most I have made in a short space of time pity it was such a small amount !!! Watch them go to 20.00 in the next weeks :)
Bought £600 shares in these in 1998 when they were SR Pharma - now worth £31.68!! Heyyyyy!!
Well we have 4's and nothing much seems to be stopping this at the mo
now looks like we may see the 4`s this week great rise but reading the info and research could have much further to go.
The uncrossing trade big volume and at the highs. Similar to a lot of days in the previous few weeks.
I also bought more way back when Avi Mortazavi got some around 1 pound ( from memory about a year ago)... For a long time I thought I had made an error!
not many people dobibed meant doubled
Yes surprises me the lack of chat on the board as I mentioned the other day. I doblbed my small holding when one of the directors bought a big chunk...quiet for a while but now have been zooming up for a good few weeks. Rather wish I had loaded up more myself
Wow. That is one amazing interview.
For me, it highlights how much this CEO is focused on driving share holder value.
Couldn't of outlined any better the appropriate company comparables as well as the numerous upcoming 'news catalysts' to drive additional share price appreciation. I still believe that this is not being valued correctly. - although I have no idea what that value is, I just suspect it is higher and possibly a lot.
He mentions Alexion acquiring Achillion - that went through at USD930m for a company working with complement medicines. As we know this is only in relation to SLN500 and the Mallinkrodt deal - to me it gives a valuation marker of today's value of those milestone payments. Yes Achillion may or may not have been further down the clinical trial pathway for complement medicines... but whatever your 'value' for the 2bn in possible future milestone payments related to SLN500 was - it has to now be higher.
https://seekingalpha.com/article/4298863-alexion-delivers-achillion-acquisition-good-deal-protect-mainstay-drug
He then goes on to talk about the LP(a) /SLN 360 being the jewel in the crown... how much would that be worth? Personally I think that is going to have a USD200m+ upfront payment on a deal + milestone payments + royalties. The type in line with Arrowhead and J&J deal for Hepatitis B.
https://www.cnbc.com/2018/10/04/jj-arrowhead-in-gene-silencing-drug-deal-worth-up-to-3point7-billion.html
As previous, i'm not a bio tech expert, just looking at the information out there and watching the excitement build. Amazed how few posts there are here on this, possibly still under the radar.
Atb and Gla